KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on this, the main mode of action of lacutamab in CTCL is currently believed to be a NK cell-mediated ADCC effect on KIR3DL2-expressing tumor T cells64–66.